⚠️ Research Use Only — Compounds discussed are research chemicals, not FDA-approved for human use. Not medical advice. Full disclaimers →
Also known as: Intranasal Synapsin, RG3 + NAD+ compound
Synapsin is a nootropic peptide research compound (not FDA-approved for human use) studied for cognitive enhancement. Synapsin is a compounded intranasal cognitive blend (Rg3 + NAD+) used by functional medicine practitioners for brain fog, TBI recovery, and cognitive enhancement. It's a compound formulation, not a single peptide. Research dose: 100–200 mcg daily. Half-life: not established. Available from COA-verified vendors with code PEPTIDEX for up to 20% off.
Sourcing data for Synapsin is updating.
We verify new listings weekly — check back soon.
Sourcing data for Synapsin is updating.
We verify new listings weekly — check back soon.
Compounded intranasal formulation (not a single peptide) combining Rg3 (ginsenoside), NAD+, and additional neuroprotective compounds. Rg3 modulates NMDA and GABA receptor activity, reduces neuroinflam
COA-verified vendors · Use code PEPTIDEX for up to 20% off
Verified pricing for Synapsin is not yet available in our database. Browse all COA-verified vendors on our price comparison tool, or check individual vendor pages.
Compare All VendorsCompounded intranasal formulation (not a single peptide) combining Rg3 (ginsenoside), NAD+, and additional neuroprotective compounds. Rg3 modulates NMDA and GABA receptor activity, reduces neuroinflammation via NF-kB inhibition, and promotes BDNF expression. NAD+ component supports mitochondrial function and sirtuin activation. Intranasal delivery bypasses blood-brain barrier. Often used in TBI, post-COVID cognitive impairment, and neurodegenerative disease support protocols.
Research only. Compounded intranasal formulation — individual components (Rg3, NAD+) have some published safety data but the specific compound blend lacks clinical trial validation. Not FDA-approved. Used in functional medicine under practitioner supervision.
See our evidence grading methodology for how we evaluate and grade peptide safety data.
* Dosing data from published literature — not a human use recommendation.
Compounded intranasal formulation; dosing varies by compounding pharmacy formulation. Rg3 typically 0.5–1mg per dose. Research use only.
Week 1
Acute cognitive effects reported; improved focus and mental clarity
Weeks 2–4
Neuroinflammation reduction in clinical observations
| Side Effect | Incidence | Severity |
|---|---|---|
Nasal irritation | ~10% | mild |
Mild headache | ~5% | mild |
Finding verified, high-purity Synapsin requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified Synapsin✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
⚠️ Educational only · Not medical advice · For research use only. Information on this page is compiled from peer-reviewed literature and is intended strictly for educational and informational purposes. Peptides discussed may be unapproved research chemicals — consult a licensed healthcare professional before considering any peptide compound. Read our full disclaimer
Affiliate disclosure: PeptiDex may earn commissions from purchases made through vendor links on this page. This does not affect our editorial ranking or vendor recommendations — we exclusively feature vendors that pass independent COA verification. See our methodology · Editorial policy
12stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.
Independent researcher, not a medical professional
PeptiDex Research is the byline used by the independent researcher who builds and maintains PeptiDex. The site is a one-person research project — there is no editorial board, no medical reviewers, and no clinical staff. Content is produced by reading...
View profile